AQST vs. RANI, CRMD, VTYX, NATR, NLTX, ME, INZY, XOMA, VNDA, and CTNM
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Rani Therapeutics (RANI), CorMedix (CRMD), Ventyx Biosciences (VTYX), Nature's Sunshine Products (NATR), Neoleukin Therapeutics (NLTX), 23andMe (ME), Inozyme Pharma (INZY), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
Aquestive Therapeutics (NASDAQ:AQST) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
In the previous week, Rani Therapeutics' average media sentiment score of 1.40 beat Aquestive Therapeutics' score of -0.95 indicating that Rani Therapeutics is being referred to more favorably in the news media.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 53.3% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aquestive Therapeutics has a beta of 2.95, indicating that its share price is 195% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.
Aquestive Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 164.03%. Rani Therapeutics has a consensus target price of $12.20, suggesting a potential upside of 147.46%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Rani Therapeutics.
Aquestive Therapeutics received 175 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 76.67% of users gave Rani Therapeutics an outperform vote while only 66.67% of users gave Aquestive Therapeutics an outperform vote.
Rani Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -55.85%. Aquestive Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.
Aquestive Therapeutics has higher revenue and earnings than Rani Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aquestive Therapeutics beats Rani Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
